Several platforms and specialized service providers map biomarkers to assays, offering practical comparisons to support drug discovery and clinical development.

• WuXi Biology offers a comprehensive biomarker platform that maps specific biomarkers to various technologies, including qRT-PCR, Meso Scale Discovery (MSD), and flow cytometry. They provide practical comparisons of different assay technologies (e.g., SYBR-Green vs. TaqMan, Western Blot vs. ELISA) for single- and multiplex assays.
• Sapient focuses on small molecule biomarker discovery, providing high-throughput untargeted analysis (rLC-MS) that allows for the simultaneous measurement of over 11,000 small molecule biomarkers. They provide comparisons highlighting the advantages of small molecule discovery over proteomics in terms of covering active biological processes.
• BioMark is a web-based platform specifically designed to streamline biomarker analysis across different omics data types. It integrates statistical methods and machine learning, allowing researchers to evaluate and compare different biomarker candidates through intuitive visualizations.
• Broad Clinical Labs offers a platform focused on biomarker discovery, specializing in high-throughput validation and application.

These platforms are designed to address the need for aligning analytical measurements with biological interpretation in clinical settings, as outlined in specialized literature.

If you'd like to narrow this down, please tell me:

• Are you focusing on small molecule, proteomic , or genomic biomarkers?
• Is this for early discovery or clinical trials?

I can provide a more tailored recommendation based on those details.

It sounds like you’re looking for a resource or platform that links specific biomarkers to available assays and ideally includes practical comparisons, such as performance, sensitivity, cost, or applicability. Here are some options that are widely used in research and clinical contexts:

---

1. BioAssay Platforms / Databases

• BioAssay Express / PubChem BioAssay

  • Maps biomolecules (including proteins and metabolites) to available assays.
  • Provides assay details like type, detection method, and activity readouts.
  • More focused on experimental screening rather than practical comparisons for clinical use.

• Cayman Chemical / Sigma Aldrich assay catalogs

  • These are commercial platforms where biomarkers (e.g., cytokines, metabolites, enzymes) can be searched.
  • They often provide side-by-side comparisons of assay types (ELISA, multiplex, colorimetric, etc.), detection limits, sample requirements, and sometimes price.

---

2. Specialized Translational Tools

• AssayMap (by companies like Thermo Fisher)

  • Maps proteins/metabolites to validated assays.
  • Includes practical considerations like throughput, automation, and sensitivity.

• Human Protein Atlas

  • Maps proteins to available detection assays (antibody-based, RNA-level detection).
  • Includes practical notes, like tissue specificity, subcellular localization, and available commercial antibodies.

---

3. Commercial Multi-Omics / Biomarker Platforms

• Olink, SomaLogic, Quanterix
  • Provide panels of biomarkers and the corresponding assay technologies.
  • Include comparisons of sensitivity, sample volume, and platform throughput.
  • Typically used in translational research and clinical biomarker studies.

---

If you want, I can make a table of platforms specifically designed to compare assays for given biomarkers, showing which ones give practical performance metrics, sample requirements, and throughput comparisons. That would give a clear “decision-making map” for experimental or clinical use.

Do you want me to make that table?

To answer this carefully, you’re asking for a platform that links biomarkers (e.g., proteins, metabolites, genes) to specific assays while also providing practical comparisons—like performance, sensitivity, cost, or suitability for different applications.

Several platforms and resources aim to do this, though they differ in scope:

---

1. Human Protein Atlas (HPA)

• What it does: Maps protein biomarkers to validated antibodies and immunoassays.
• Practical comparisons: Shows expression patterns across tissues and cells, antibody validation data (useful for choosing assays).
• Pros: Free, widely used, detailed tissue and cellular context.
• Cons: Mostly for protein biomarkers; less on metabolites or functional assays.

Website:

---

2. ClinicalTrials.gov + Bioinformatics Tools

• What it does: By searching for a biomarker, you can find associated assays used in trials.
• Practical comparisons: Can infer which assays are clinically validated or commonly used.
• Pros: Links biomarkers to real-world clinical assay use.
• Cons: No centralized side-by-side comparison table.

---

3. AssayMap / assaycomparison platforms (commercial)

• Examples: Thermo Fisher Scientific, Bio-Rad, Qiagen, and Myriad RBM provide biomarker-to-assay mapping in their catalogs. Some platforms allow filtering by assay type, sensitivity, throughput, and species.
• Pros: Practical, ready-to-use comparisons for experimental planning.
• Cons: Commercial; may not cover all biomarkers.

---

4. PubChem BioAssay / ChEMBL

• What it does: Maps small-molecule or gene-based biomarkers to bioassays.
• Practical comparisons: You can see assay conditions, readouts, and sometimes assay quality metrics.
• Pros: Open-access; extensive bioactivity data.
• Cons: More chemical/compound focused; less on clinical biomarker assays.

---

5. Open Platforms for Biomarker Assay Evaluation

• Example: BioAssay Express (academic) or Assay Guidance Manual by NCATS
• What it does: Provides protocols, assay selection guidance, and performance metrics.
• Pros: Educational and comparative.
• Cons: Not always a full database of biomarkers.

---

💡 Summary Recommendation:

• For protein biomarkers → Human Protein Atlas
• For clinical biomarker assays → Commercial assay comparison tools (Thermo Fisher, Bio-Rad, Qiagen)
• For small molecules / gene assays → PubChem BioAssay or ChEMBL

---

If you want, I can make a table comparing the top 5 platforms showing: biomarker type, assay coverage, practical comparison info, and access type. It would give a clear “at-a-glance” guide.

Do you want me to do that?

The most specialized, user-accessible online platform that maps disease-specific biomarkers directly to their translational assays alongside practical, evidence-based comparisons is Bm2Dx (TB Biomarker Database) . Developed by FIND in collaboration with McGill University, this platform acts as a landscape tracker, enabling researchers to search biomarker candidates, evaluate validation data, and gauge how well they match real-world Target Product Profiles (TPPs) for diagnostic assays.

If you are looking at this from a general bioanalytical, commercial, or platform-wide comparison perspective, several key databases and resources serve this purpose across different scientific domains:

1. General Bioanalytical Platform Maps

When comparing which physical instrument or technology platform is best for matching a protein biomarker to a high-throughput assay, research frequently relies on head-to-head performance metrics.

• Immunoassay Competitors : When comparing multi-target profiling, peer-reviewed resources systematically cross-examine platforms like Meso Scale Discovery (MSD) S-PLEX/V-PLEX, Olink (Proximity Extension Assay), Quanterix Simoa , and Luminex (xMAP).
• The Practical Comparison Metrics : These platforms are routinely mapped based on reagent cost, sample volume efficiency, hands-on labor time , and overall detectability (e.g., MSD often exhibits higher raw detectability percentages, whereas Olink excels in massive multiplexing capacity).

2. Specific Digital and Molecular Repositories

• The BioMAP Platform by Eurofins Discovery : An enterprise platform mapping compound effects to over 4,500 translational human primary cell disease models. It generates practical "toxicity and efficacy signatures" by comparing new candidates against a massive reference library of clinically approved agents.
• The Plasma Metabolome–Phenome Atlas : An interactive, browsable web tool that maps tens of thousands of metabolite-trait and metabolite-disease associations using longitudinal data. It allows practical evaluation of classification performances (AUC scores) across multiple indications.
• BioMark (Biomarker Analysis Tool) : A web platform focused on streamlining analytical multi-omics discovery. It features a practical feature-ranking strategy that consolidates calculations from multiple different machine learning algorithms to confirm validation metrics.

Summary Comparison of Leading Platforms

Are you exploring this to find a specific clinical database for a disease layout, or are you trying to choose the best lab equipment/technology platform for an upcoming experimental project?

Yes—there are platforms that explicitly map biomarkers to assays and even allow practical comparisons , but they’re relatively niche and often used in pharma/biotech rather than widely marketed SaaS tools. The ones closest to what you’re describing fall into two categories: curated biomarker–assay databases and integrated research platforms.

---

1) Dedicated biomarker → assay mapping platforms (closest match)

Beacon Biomarker & Assay Database

• This is one of the clearest examples of what you’re asking for.

• It maps biomarkers to assays and clinical trials , letting users see:

• which assays were used for a given biomarker

• in what context (trial phase, indication, etc.)

• Built using AI + manual curation of global research data.

• Designed to support decision-making and comparison across assay strategies. biospace.com

👉 If your goal is “show me all assays used for biomarker X and compare them in practice” , this is very close.

---

BiomarkerBay

• A searchable biomarker–assay database (more lightweight).

• Lets you look up:

• biomarker ↔ assay relationships

• validation level (exploratory → clinical)

• Comparison is more manual (not deeply analytical), but still useful for quick mapping and discovery. biomarkerbay.com

---

2) Platforms with assay comparison capability (but not purely mapping-first)

EATRIS Biomarkers Platform

• Focuses on validation + comparison of biomarker assays across technologies.

• Provides:

• standardized assay development

• testing and comparison of multiple assay approaches

• Strong for practical benchmarking , less of a searchable database UI. eatris.eu

---

Motif Biomarker Research Platform

• Integrates multiple databases (PubMed, ClinVar, etc.)

• AI-driven workflows to:

• identify biomarkers

• connect evidence (including assays indirectly via literature)

• Good for research exploration , but assay comparison is inferred rather than structured. motif.bio

---

3) Important nuance (why these are rare)

Most “platforms” in this space are actually:

• Service providers (e.g., CROs offering ELISA, LC-MS, flow cytometry, etc.)

• Or technology stacks rather than mapping tools

This is because:

• The “best assay” depends heavily on context (matrix, sensitivity, throughput, cost)

• Multiple platforms (e.g., LC–MS, ligand-binding assays, flow cytometry) may all be valid for the same biomarker tandfonline.com

So true standardized comparison layers are still emerging.

---

Bottom line

• If you want direct biomarker → assay mapping with usable comparisons :

• Best fit: Beacon Biomarker & Assay Database

• Secondary: BiomarkerBay

• If you want hands-on comparison / validation of assay approaches :

• Best fit: EATRIS Biomarkers Platform

• If you want broader discovery + literature-linked insights :

• Consider: Motif

---

If you tell me your use case (e.g., drug development vs diagnostics vs omics research), I can narrow this to the most practical platform—or suggest tools that feel closer to a “Gartner-style comparison layer,” which is still a gap in this space.

Several specialized platforms, databases, and CRO services map biomarkers to assays, offering practical comparisons of sensitivity, sample volume, and throughput. Rules Based Medicine (RBM/IQVIA) offers specialized comparisons of Simoa and Olink assays, while Meso Scale Discovery (MSD) is widely used for comparing multiplexed immunoassay performance. The Clinical Biomarker App helps prioritize biomarkers based on clinical data.

Key Platforms and Comparative Tools:

• Rules Based Medicine (RBM/IQVIA) : Maps specific analytes (e.g., AD-related markers) to highly sensitive technologies like Single Molecule Array (Simoa) and Olink Proximity Extension Assay (PEA).
• Meso Scale Discovery (MSD) : Frequently compared against Bio-Plex for high-throughput cytokine profiling, offering S-PLEX (high sensitivity) and V-PLEX (validated) options.
• NULISA/Olink Comparison Studies : NULISA (nucleic acid-linked) and Olink (PEA) are often compared for low-volume (1-30 µL) multiplexing, showing high performance for protein markers.
• Clinical Biomarker App : A resource that maps over 3,000 biomarkers to 2,600 diseases, useful for selecting and prioritizing biomarkers based on clinical trial data.
• Targeted LC–MS/MS : Central to comparing structural specificity and quantitative robustness for diverse biomarkers, particularly in early development.
• Sigama-Aldrich MILLIPLEX® : Provides a structured guide to selecting between multiplex platforms and targeted ELISAs.

These platforms help bridge the gap between biomarker discovery and validated, fit-for-purpose assays, essential for clinical trial applications.

Several platforms and services map biomarkers to assays, offering practical comparisons for sensitivity, specificity, and throughput:

• Rules Based Medicine (RBM/IQVIA) : Provides comparisons and services for Simoa (ultrasensitive), Olink (PEA technology), and multiplex immunoassay platforms to map protein biomarkers to appropriate assays.
• Engine Biosciences (NetMAPPR) : Combines biology and AI to map biomarkers to targets and validate them across different assays.
• BioMark (PMC12896108) : A web-based platform for identifying and analyzing biomarkers using integrated machine learning.
• Sigma-Aldrich (MILLIPLEX®) : Offers tools to choose between MILLIPLEX®, ELISA, or SMC® platforms based on biomarker requirements.
• Comparison Studies (PMC12618483) : Independent studies provide direct comparisons of multiplex immunoassays (e.g., MSD vs. Olink vs. NULISA).

Key platforms for protein biomarker measurement include ELISA, MS-based methods (LC-MRM MS), and specialized immunoassay technologies such as Olink and MSD.

Several platforms exist that map biomarkers to assay technologies and provide practical side-by-side comparisons , but they fall into a few distinct categories depending on whether you want wet-lab assay selection or data-driven biomarker discovery/analysis.

Here are the most relevant ones:

---

1) Assay technology & biomarker platform providers (most practical for lab selection)

These are the most “real-world useful” if your goal is: “Which assay should I use for biomarker X?”

Olink (PEA proteomics platform)

Olink
Olink provides one of the clearest biomarker-to-assay mappings in practice through its protein biomarker library.

• Maps >5,000 protein biomarkers to validated assays

• Each biomarker is linked to Proximity Extension Assay (PEA) panels

• Built-in guidance for:

• sensitivity

• sample type (serum/plasma/etc.)

• multiplexing level

• Strong “assay selection logic” for translational studies
  olink.com

👉 Practical takeaway: best for protein biomarker → ready assay panel selection at scale

---

Luminex / MSD / ELISA comparison platforms

Luminex and Meso Scale Discovery

These are commonly used “assay decision frameworks” in CROs and pharma.

They explicitly compare:

• Luminex → bead-based multiplex immunoassays

• MSD (Meso Scale Discovery) → electrochemiluminescence multiplex assays

• ELISA → singleplex gold standard

They help map:

• biomarker type → assay modality

• required sensitivity → platform choice

• multiplex need → technology selection

catalog.labcorp.com +1

👉 Practical takeaway: best for choosing assay modality (not just biomarker lookup)

---

2) Integrated biomarker discovery + analysis platforms (software-based mapping)

These are closer to what you described as “biomarker ↔ assay mapping with comparison logic.”

BioMark (web biomarker analysis platform)

BioMark platform

A research-facing platform that:

• integrates biomarker datasets (omics-scale)

• ranks biomarkers via multiple statistical methods

• helps move from raw data → validated biomarker sets

• supports classification models and comparison workflows

link.springer.com

👉 Practical takeaway: best for computational biomarker prioritization , not wet-lab assay selection

---

3) Clinical / CRO biomarker platforms (most “end-to-end practical”)

These don’t always look like software tools, but in practice they function as mapping systems.

Example: integrated CRO platforms like:

• multiplex immunoassay menus

• LC-MS biomarker panels

• flow cytometry panels

• histopath + molecular assay mapping

Example capabilities (typical CRO stacks):

• biomarker → recommended platform (flow, LC-MS, MSD, qPCR)

• matrix compatibility (plasma, tissue, CSF)

• assay validation status (discovery vs clinical-grade)

wuxibiology.com +1

👉 Practical takeaway: best for translating biomarkers into validated lab workflows

---

Bottom line (what actually matches your question)

If you specifically want “a platform that maps biomarkers to assays AND lets you compare options practically” , the closest matches are:

🥇 Most direct (biomarker → assay selection)

• Olink platform ecosystem

• MSD / Luminex assay libraries

🥈 Best for decision-making across assay types

• CRO integrated biomarker platforms (LC-MS, immunoassays, flow cytometry menus)

🥉 Best computational mapping (data-side, not lab-side)

• BioMark-style biomarker analytics platforms

---

Quick interpretation

• Need wet-lab assay choice? → Olink / MSD / Luminex ecosystems

• Need cross-platform comparison? → CRO biomarker service platforms

• Need computational prioritization? → BioMark-type tools

---

If you tell me your use case (drug discovery, clinical trial design, diagnostics, etc.), I can narrow this down to the exact platform stack people typically use in that setting.

Several platforms and technologies map biomarkers to assays, offering practical comparisons for sensitivity and sample volume. Key platforms include MSD (Meso Scale Discovery), Olink, and NULISA, which are frequently compared for multiplex immunoassay performance, with MSD often showing high detectability. The MILLIPLEX® platform is also used to screen biomarkers and connect them to targeted assays.

Platform Comparisons & Mapping Tools

• Multiplex Immunoassays: Studies directly compare MSD , NULISA , and Olink for protein biomarkers, analyzing detectability and correlation across platforms. NULISA and Olink require low sample volumes (1–30 µL) and offer high-throughput analysis.
• Targeted Assays: MILLIPLEX® (multiplex) and Conferma® ELISAs (targeted) are used together to move from discovery to validation.
• Protein Assays: The Jess Automated Western Blotting system acts as a bridge between traditional Western blots and ELISAs, providing quantification of total and phosphorylated proteins.
• Mass Spectrometry (LC–MS/MS): Used for highly robust, specific quantitative analysis of metabolites and proteins.
• Other Platforms: Engine Biosciences ' NetMAPPR utilizes network biology to link biomarkers to targets, while SMC® (Single Molecule Counting) technology offers high-sensitivity protein detection.

For specific assay choices based on clinical validation, platforms like bead-based SPR systems are used for kinetic studies.

Short answer: there isn’t a single dominant “Google Maps–like” platform that cleanly maps biomarkers → available assays with side-by-side practical comparisons. Most solutions are fragmented across (1) assay vendors, (2) omics platforms, and (3) internal or semi-private knowledgebases. But a few categories—and some specific platforms—get close depending on what you mean by “practical comparisons.”

---

🧭 1) Closest thing to platform-level comparisons (but not true mapping tools)

These are assay platforms themselves that are frequently compared head-to-head in literature:

Major multiplex biomarker platforms

• Meso Scale Discovery

• Olink

• Luminex

• Quanterix

What you get:

• Published comparisons of sensitivity, multiplexing, dynamic range

• Example: MSD vs Olink vs NULISA comparisons show big differences in detectability and sensitivity nature.com

• Simoa often leads in ultra-sensitivity, while Luminex/MSD are more mid-plex, cost-effective options pubmed.ncbi.nlm.nih.gov

What you don’t get:

• A unified interface where you input a biomarker and see all assay options ranked

👉 These are hardware/assay ecosystems , not discovery/mapping tools.

---

🧪 2) Vendor ecosystems with partial “biomarker → assay” mapping

Some platforms bundle assay catalogs + analysis software , which is the closest thing to what you’re describing:

Example:

• Belysa (used with Luminex assays)

What they offer:

• Libraries of validated assays tied to biomarkers

• Multiplex panels (e.g., cytokines, oncology markers)

• Built-in comparison within their own ecosystem

Limitation:

• Closed world — only compares assays within that vendor’s technology stack merckmillipore.com

---

🧬 3) “Meta-layer” resources (closest to what you want conceptually)

These are not perfect, but they approximate a biomarker→assay map:

a) Scientific literature + benchmarking studies

• Cross-platform comparison papers (like the one above)

• Pros: real performance data

• Cons: manual synthesis required

---

b) Internal pharma / CRO tools (not public)

Companies and CROs (e.g., biomarker service providers) often maintain:

• Internal databases mapping:

• biomarker

• assay type (ELISA, PEA, bead-based, NGS)

• platform performance

• These are exactly what you’re describing—but proprietary

---

c) Emerging AI / data platforms

• Experimental systems like ORCA focus on discovery and analysis rather than assay selection

• Digital biomarker platforms (e.g., JTrack) map signals, not wet-lab assays

👉 These are adjacent—but not solving assay comparison yet.

---

⚖️ Reality check: why your “ideal platform” barely exists

What you’re asking for is hard because:

1. Assays are context-dependent

• Sample type (serum, tissue, FFPE)

• Required sensitivity

• Multiplex vs singleplex

2. Performance varies per biomarker

• Same platform may be great for IL-6 but poor for another protein

3. Vendors silo data

• No incentive to provide cross-platform comparisons

---

🧩 If you want something practical today

Here’s the closest workflow people actually use:

1. Start with biomarker list

2. Check:

• Olink panel availability

• MSD V-PLEX panels

• Luminex MILLIPLEX kits

3. Cross-check literature for:

• sensitivity

• detection rates

4. Validate with a CRO if high stakes

---

🧠 Bottom line

• There is no single platform that cleanly maps biomarkers → assays with objective, cross-vendor comparisons

• The closest approximations are:

• Platform ecosystems (Olink, MSD, Luminex)

• Published benchmarking studies

• Internal pharma/CRO databases (not public)

---

If you want, tell me:

• your biomarker type (proteins, RNA, methylation, etc.)

• use case (discovery vs clinical vs validation)

…and I can point you to the closest real tools or workflows that match your exact scenario.